Idiopathic Hypersomnia

Idiopathic Hypersomnia (IH) is a rare yet debilitating sleep disorder that can profoundly impact daily life and overall well-being. It is characterized by excessive daytime sleepiness despite prolonged nighttime sleep, often accompanied by difficulty waking up and feelings of grogginess or “sleep inertia.” People with IH may struggle to stay awake and alert, which can affect their ability to work, study, and engage in social activities. Without proper treatment, IH can significantly reduce quality of life and productivity.

Advances in sleep research have provided valuable insights into the mechanisms underlying IH, although its exact cause remains unclear. These discoveries are driving the development of targeted therapies aimed at managing excessive sleepiness and improving wakefulness. Current treatments include wake-promoting medications and lifestyle strategies, which, when tailored to individual needs, can help alleviate symptoms and improve functioning.

At iNGENū, we are committed to advancing research and innovation for Idiopathic Hypersomnia. By combining cutting-edge science with a patient-centered approach, our team strives to accelerate the development of effective treatments, offering hope and improved quality of life for individuals and families affected by this challenging condition.

 

3x

more common in women than men

 

 

40%

of individuals with IH report long, unrefreshing naps that don't alleviate tiredness

 

 

60%

of patients report worsening symptoms during periods of stress or illness





Our clinical team has over

120

years of combined clinical trial experience

Download Our Paper

Fill out this form to download our white paper on how to overcome the biggest obstacles in conducting a Idiopathic Hypersomnia trial.

iNGENu CRO - Idiopathic Hypersomnia

In light of the impact Idiopathic Hypersomnia has on individuals and society as a whole, continued research efforts are crucial to improve diagnosis, treatment, and ultimately, patients' quality of life.

The development of clinical trial protocols that meet FDA approval standards is crucial for the success of new Idiopathic Hypersomnia treatments.